Actively Recruiting
Assessment of Spondyloarthritis in Patients with Acute Anterior Uveitis: A Prospective Observational Study Comparing HLA-B27-positive and -negative Cases
Led by Marmara University · Updated on 2024-12-06
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Spondyloarthritis (SpA) refers to a group of inflammatory rheumatic diseases that cause joint inflammation and other symptoms like eye inflammation (acute anterior uveitis or AAU) and skin problems. Axial spondyloarthritis (axSpA) mainly affects the spine and can lead to vertebral fusion in advanced stages. The disease is more common in men and usually starts in young adulthood. Diagnosing axSpA involves imaging and clinical signs, and disease activity is tracked with specific indices. AAU is the most frequent eye-related symptom of SpA, often linked to a genetic marker called HLA-B27, and can cause serious eye issues if untreated. This research aims to study how common SpA is among patients with AAU and to explore clinical features based on HLA-B27 status in an ophthalmology setting. This is an observational study without drug treatments, focusing on patients who come to eye clinics with AAU. Researchers will follow a group of patients who have AAU to check for signs of axial and peripheral SpA using established classification criteria. The study will compare patients with and without the HLA-B27 marker to understand differences. Data will be collected over several years, with cross-sectional analyses planned after two and five years to assess SpA prevalence and incidence among these patients. Participants will be adults aged 18 to 75 who have uveitis but have not been previously diagnosed with SpA before their eye symptoms. The study involves clinical evaluations, imaging, and laboratory tests to classify SpA presence, along with monitoring of disease characteristics and genetic markers. The main outcomes include measuring the prevalence and incidence of SpA in AAU patients, comparing HLA-B27 status, and understanding clinical features. The study will help improve knowledge about the link between eye inflammation and SpA and guide future treatment and follow-up strategies.
CONDITIONS
Brief Title
Observational Prospective Turkish Inception Cohort of Uveitis and Spondyloarthritis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with uveitis
- Aged between 18 and 75 years
You will not qualify if you...
- Patients diagnosed with spondyloarthritis before their uveitis attack
- Patients with infectious uveitis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants undergo assessments to evaluate the presence of spondyloarthritis and HLA-B27 status.
1 to 2 visits depending on diagnostic needs
Duration - Up to 5 years
Participants are observed over time to assess the incidence and prevalence of spondyloarthritis following acute anterior uveitis diagnosis.
Periodic visits over the study duration
Trial Site Locations
Total: 1 location
1
Marmara University School of Medicine
Istanbul, Maltepe, Turkey (Türkiye), 34854
Actively Recruiting
Research Team
M
Mehmet P ATAGUNDUZ, MD
Ş
Şeyma ÇOLAKOĞLU-ÖZKAYA, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here